百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ONC 百济神州

未开盘 02-11 16:00:00 EST

351.27

-2.16

-0.61%

盘后351.27

+0.000.00%

19:53 EST

最高354.01	最低345.02	成交量11.08万
今开353.45	昨收353.43	日振幅2.54%
总市值418.01亿	流通市值265.71亿	总股本1.19亿
成交额3,872万	换手率0.15%	流通股本7,564万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":351.27,"timestamp":1770843600000,"preClose":353.43,"halted":0,"volume":110821,"hourTrading":{"tag":"盘后","latestPrice":351.27,"preClose":351.27,"latestTime":"19:53 EST","volume":1020,"amount":358325.022,"timestamp":1770857604541,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0061115355233003,"floatShares":75641900,"shares":119000000,"eps":0.5204,"marketStatus":"未开盘","change":-2.16,"latestTime":"02-11 16:00:00 EST","open":353.45,"high":354.01,"low":345.02,"amount":38721655.3112,"amplitude":0.025436,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.5204,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770886800000},"marketStatusCode":0,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":353.43,"preHourTrading":{"tag":"盘前","latestPrice":353.43,"preClose":353.43,"latestTime":"09:08 EST","volume":13,"amount":4600.94752,"timestamp":1770818936308,"change":0,"changeRate":0,"amplitude":0.017988},"postHourTrading":{"tag":"盘后","latestPrice":351.27,"preClose":351.27,"latestTime":"19:53 EST","volume":1020,"amount":358325.022,"timestamp":1770857604541,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.389475,"impliedVol":0.468,"impliedVolPercentile":0.6454},"requestUrl":"/m/hq/s/ONC/wiki","defaultTab":"wiki","newsList":[{"id":"2610990656","title":"百济神州：公司会在定期报告中面向所有投资者统一披露截至相应报告期末的股东户数","url":"https://stock-news.laohu8.com/highlight/detail?id=2610990656","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610990656?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:05","pubTimestamp":1770645946,"startTime":"0","endTime":"0","summary":"证券日报网讯2月9日，百济神州在互动平台回答投资者提问时表示，公司在已披露的2025年第三季度报告中公布，截至2025年9月30日，公司普通股的登记股东有36164户（其中包括人民币股份登记股东36008户，41户登记在港股股东名册及115户登记在瑞士股东名册的股东）和8户美国存托股份的记录持有人，合计36172户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602093645740228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","BK1500","BK4585","LU0588546209.SGD","BK1583","LU2328871848.SGD","LU0307460666.USD","LU1719994722.HKD","688235","BK1161","LU1303224171.USD","06160","BK4526","BK1588","LU1770034418.SGD","ONC","BK0239","BK4139","LU1251922891.USD"],"gpt_icon":0},{"id":"2607018875","title":"百济神州(06160)授出涉及2.1万股美国存托股份的受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2607018875","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607018875?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:54","pubTimestamp":1769763247,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年1月23 日，董事会薪酬委员会根据2016期权及激励计划的条款向二百四十六名承授人授出涉及合共2.1万股美国存托股份的受限制股份单位。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1588","BK4526","LU1303224171.USD","LU1969619763.USD","BK4139","LU1251922891.USD","LU0588546209.SGD","BK0239","LU1719994722.HKD","LU0307460666.USD","BK1500","LU2328871848.SGD","ONC","688235","06160","BK1161","BK4585","LU1770034418.SGD"],"gpt_icon":0},{"id":"2606979167","title":"中国上市、全球首发！百济神州这一创新药开启血液肿瘤治疗新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2606979167","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606979167?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:17","pubTimestamp":1769591825,"startTime":"0","endTime":"0","summary":"百济神州新型BCL2抑制剂索托克拉（百悦达）中国上市会暨全球首发盛典日前举行。会上，众多专家共同就国内慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）以及套细胞淋巴瘤（MCL）的诊疗现状、治疗策略及创新诊疗格局展开分享与讨论，以期推动创新药物更好地造福国内患者。近年来，我国血液肿瘤的防治依然面临严峻挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601283633690762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","159992","LU0329678337.USD","BK4526","BK1500","06160","ONC","LU0737861772.HKD","BK1574","688235","BK4585","06078","BK1583","06978","BK1588","LU2488822045.USD","LU1969619763.USD","LU0307460666.USD","BK1209","LU1251922891.USD","LU1719994722.HKD","LU0588546209.SGD","LU0329678170.USD","LU1770034418.SGD","LU1303224171.USD","BK0239","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2604900915","title":"中金港股通与恒指调整预览：紫金黄金国际(02259)等有望纳入恒指 预计44只公司有望入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2604900915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604900915?lang=zh_cn&edition=full","pubTime":"2026-01-19 14:03","pubTimestamp":1768802591,"startTime":"0","endTime":"0","summary":"考虑到恒生指数编算细则中明确指出，恒指将保留至少20只被认定为香港公司的成分股，此数目至少每两年检讨一次，不排除此次会“递补”其他香港公司进入恒生指数的可能。港股通调整：预计44只有望入通；25只或被移出此次也适逢恒生综合指数的年度审议。此外，部分公司预计分别将于1月28日与2月10日从港交所退市，届时也将被移出港股通交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0593848301.USD","02328","HK0000252160.HKD","513600","601601","ONC","HHImain","YUMC","06160","HK0000500386.USD","02601","HK0000252152.HKD","LU2213484517.USD","BK1198","SGXZ86797644.SGD","09926","LU2543165471.USD","BK4614","02259","688235","SGXZ62798434.SGD","06181","MCHmain","09987","02833"],"gpt_icon":1},{"id":"2603576836","title":"百济神州(06160.HK)高开逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576836","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603576836?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:36","pubTimestamp":1768354599,"startTime":"0","endTime":"0","summary":"每经AI快讯，百济神州(06160.HK)高开逾3%，截至发稿涨3.33%，报210.8港元，成交额1678.72万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143618443468.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143618443468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1588","BK4526","LU1303224171.USD","LU1969619763.USD","BK4139","LU1251922891.USD","LU0588546209.SGD","BK0239","LU1719994722.HKD","LU0307460666.USD","BK1500","LU2328871848.SGD","ONC","688235","06160","BK1161","BK4585","LU1770034418.SGD"],"gpt_icon":0},{"id":"2603652978","title":"港股异动 | 百济神州(06160)高开逾3% 宣布百悦达®在中国商业化上市 首批药品将覆盖全国70个城市","url":"https://stock-news.laohu8.com/highlight/detail?id=2603652978","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603652978?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:30","pubTimestamp":1768354233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州高开逾3%，截至发稿，涨3.33%，报210.8港元，成交额1678.72万港元。消息面上，1月14日，据百济神州官微消息，公司宣布其自主研发的1类新药新型BCL2抑制剂百悦达已于1月13日启动供应，首批药品将覆盖全国70个城市。研究结果证实，在经治CLL/SLL及R/R MCL患者中，索托克拉显示出具有临床意义的缓解获益，同时整体耐受性与安全性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","LU1969619763.USD","688235","LU1303224171.USD","BK1161","BK4585","LU1770034418.SGD","LU1251922891.USD","BK1500","LU0307460666.USD","LU2328871848.SGD","BK4139","BK1583","ONC","BK4526","LU1719994722.HKD","06160","LU0588546209.SGD","BK0239"],"gpt_icon":0},{"id":"2603616871","title":"百济神州盘中异动 临近收盘股价大涨5.34%报351.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616871","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603616871?lang=zh_cn&edition=full","pubTime":"2026-01-14 04:54","pubTimestamp":1768337695,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日04时54分，百济神州股票出现异动，股价大幅上涨5.34%。截至发稿，该股报351.83美元/股，成交量29.9905万股，换手率0.27%，振幅4.40%。百济神州股票所在的生物技术行业中，整体跌幅为0.10%。百济神州有自己的团队进行全球临床试验。截至2024年，其核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的60%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011404545597a1ab33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011404545597a1ab33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4585","BK4139"],"gpt_icon":0},{"id":"2603308697","title":"医药生物行业周报：聚焦脑机接口与小核酸药物 JPM盛会前奏下医疗布局新浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2603308697","media":"东方财富证券股...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603308697?lang=zh_cn&edition=full","pubTime":"2026-01-14 00:00","pubTimestamp":1768320000,"startTime":"0","endTime":"0","summary":"本周港股116 支医药生物个股中，104 支上涨，占比89.66%。脑机接口建议关注诚益通、伟思医疗、麦澜德等。本周，小核酸创新药优质企业瑞博生物-B 上市，二级市场表现火热。第44 届摩根大通医疗健康年会将于当地时间2026 年1月 12 日-15 日在美国旧金山盛大举办。根据JPM 大会官网已公布的日程，有超 20 家中国公司将出席本届会议并发表演讲。关注会议公布重磅研发进展数据，建议关注百济神州、恒瑞医药、三生制药等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114184732a4c2efbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114184732a4c2efbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02228","BK1141","02192","BK1617","ONC","06127","06160"],"gpt_icon":1},{"id":"1155268538","title":"百济神州：伯恩斯坦上调评级至跑赢大市，目标价升至414美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155268538","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155268538?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:21","pubTimestamp":1768216910,"startTime":"0","endTime":"0","summary":"伯恩斯坦研究机构宣布，将百济神州的投资评级从\"与大市同步\"提升至\"跑赢大市\"，同时将其目标股价从362美元大幅上调至414美元。这一调整反映了该机构对百济神州未来发展前景的积极预期。\n此次评级上调基于对公司核心业务增长潜力的重新评估，目标价的上调幅度达到14.4%，显示出分析师对该公司价值的认可。伯恩斯坦认为，百济神州在创新药物研发和商业化方面展现出的优势，有望推动其业绩实现超预期表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","BK4526","688235","BK4139","BK4585","BK0239"],"gpt_icon":0},{"id":"2601787308","title":"百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2601787308","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601787308?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:49","pubTimestamp":1767775792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年12月31日，董事会及╱或董事会薪酬委员会根据2016期权及激励计划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制股份单位相当于69.32万股股份，约占本公告之日公司发行股份总数的0.04%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1719994722.HKD","LU1969619763.USD","LU1251922891.USD","LU0588546209.SGD","BK1161","BK1583","06160","BK4526","BK4139","LU1770034418.SGD","BK4585","ONC","LU1303224171.USD","BK1500","688235","BK1588","LU2328871848.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"1170001608","title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1170001608","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170001608?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:02","pubTimestamp":1767697320,"startTime":"0","endTime":"0","summary":"1月6日，$百济神州$宣布，其自研的1类新药新型BCL2抑制剂百悦达获得国家药品监督管理局附条件批准，用于治疗既往接受过至少包含布鲁顿酪氨酸激酶抑制剂在内的一种系统治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤成人患者，以及既往接受过至少两种系统性治疗的复发或难治性套细胞淋巴瘤成人患者。基于此次获批，索托克拉将为已接受过BTK抑制剂治疗的CLL/SLL患者带来新的治疗选择，更使其成为国内首款且唯一可用于治疗MCL的BCL2抑制剂。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1719994722.HKD","LU1969619763.USD","BK1500","LU1251922891.USD","06160","BK4585","LU2328871848.SGD","ONC","688235","LU1303224171.USD","BK1583","LU0307460666.USD","BK0239","BK4139","BK1588","BK4526","LU0588546209.SGD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2601917854","title":"重磅，百济神州又一款1类新药迎来新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2601917854","media":"北京药研汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601917854?lang=zh_cn&edition=full","pubTime":"2026-01-06 08:01","pubTimestamp":1767657678,"startTime":"0","endTime":"0","summary":"特应性皮炎，这一慢性、复发性、炎症性皮肤病，近年来在全球范围内发病率持续上升，给患者的生活质量带来了严重影响。BGB-45035是百济神州开发的一款IRAK4 CDAC，正被研究用于治疗各类自身免疫性疾病。据报道，该药物具有潜力诱导更深、更快的IRAK4降解，并且细胞因子抑制作用更强，是百济神州在自有CDAC平台上研发的第二款靶向降解剂。IRAK4作为先天免疫关键靶点，近年来受到多家药企关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106081138a6f7b13c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106081138a6f7b13c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526","BK4585","06160"],"gpt_icon":0},{"id":"2601854186","title":"千亿出海潮：中国创新药企驶入全球深水区","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854186?lang=zh_cn&edition=full","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01167","BK4139","BK4526","02509","06160","BMS","01801","ONC","CXO","01541","BK4585","00013"],"gpt_icon":0},{"id":"2601854164","title":"百济神州盘中异动 早盘急速上涨5.44%报327.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854164?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:31","pubTimestamp":1767623486,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时31分，百济神州股票出现波动，股价急速上涨5.44%。截至发稿，该股报327.95美元/股，成交量2.6425万股，换手率0.02%，振幅2.00%。百济神州股票所在的生物技术行业中，整体跌幅为0.32%。百济神州有自己的团队进行全球临床试验。截至2024年，其核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的60%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223126a49f633b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223126a49f633b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2601854118","title":"百济神州BG - C0902启动Ⅰ期临床 适应症为晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854118","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854118?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:30","pubTimestamp":1767609000,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，广州百济神州生物制药有限公司的一项探索靶向 EGFR×MET 的抗体偶联药物 BG - C0902 单药治疗和与其他治疗药物联合用药治疗晚期实体瘤患者的安全性、耐受性、药代动力学、药效学和初步抗肿瘤活性的1a/1b 期研究已启动。BG - C0902 为生物制品，适应症为晚期实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105183358a6f59bce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105183358a6f59bce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0385154629.USD","BK4526","LU0048573561.USD","LU0251142724.SGD","ONC","BK4588","BK4189","BK4585","LU0471298777.SGD","BK4139","LU2211817866.USD","LU0471298694.HKD","LU0742534661.SGD","LU0251131958.USD","LU2360106947.USD","BG"],"gpt_icon":0},{"id":"2601800005","title":"百济神州BCL-2抑制剂“索托克拉”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601800005","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601800005?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:19","pubTimestamp":1767608340,"startTime":"0","endTime":"0","summary":"1 月 5日，NMPA 官网显示，百济神州BCL-2抑制剂“索托克拉”两项适应症中国获批上市，适用于治疗既往接受过治疗的慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤成人患者，以及治疗既往接受过抗CD20治疗和BTKi治疗的套细胞淋巴瘤成人患者。索托克拉是百济神州开发的一款强效、高选择性BCL-2抑制剂，其设计旨在产生更深、更持久的靶点抑制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-01-05/doc-inhfhavn6767115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0307460666.USD","LU1969619763.USD","BK1588","LU1770034418.SGD","BK4526","BK1161","BK4139","BK0239","BK4585","LU0588546209.SGD","LU1719994722.HKD","ONC","LU1303224171.USD","LU2328871848.SGD","LU1251922891.USD","BK1583","BK1500","06160","688235"],"gpt_icon":0},{"id":"2593477930","title":"国内商保发展和集采优化 创新药产业链持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477930","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593477930?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:11","pubTimestamp":1766581900,"startTime":"0","endTime":"0","summary":"随着国内商保发展和集采优化，创新药产业链高景气有望延续。当前支持创新药产业发展已成为政策导向，2025年北京、上海、重庆、四川等多地出台相关政策，推动创新药行业高质量发展。近日，2026年医保药品目录和商保药品目录发布，首次在基本医保目录之外增设商保创新药目录。创新药长期产业趋势确定，在国内政策支持以及美联储进入降息周期的背景下，全球创新药研发持续活跃，2026年还有大量BD落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BPRC5H50.USD","LU0417516902.SGD","01801","LU1794554557.SGD","LU0348827113.USD","BK1161","LU0348784397.USD","LU0417516571.SGD","LU0634319403.HKD","LU0348767384.USD","LU2399975544.HKD","LU0348735423.USD","LU2476274308.USD","09926","LU0348783233.USD","LU0348766576.USD","LU2488822045.USD","LU2476274720.SGD","LU0561508036.HKD","BK1574","IE00B5MMRT66.SGD","01276","LU0417516738.SGD","LU0540923850.HKD","01877","LU1961090484.USD","LU2778985437.USD","IE00B543WZ88.USD","06978","ONC","LU1720050803.USD","LU0348825331.USD"],"gpt_icon":0},{"id":"2594405085","title":"21专访丨高特佳投资副总经理于建林：锚定下一代疗法 创新药行业走向价值深化","url":"https://stock-news.laohu8.com/highlight/detail?id=2594405085","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594405085?lang=zh_cn&edition=full","pubTime":"2025-12-24 07:00","pubTimestamp":1766530800,"startTime":"0","endTime":"0","summary":"高特佳投资集团副总经理于建林在接受21世纪经济报道记者专访时也指出，中国创新药行业已迈入高质量发展新阶段。于建林进一步表示。2026年港股依旧是中国未盈利创新药企业上市的核心阵地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224070019a6c78236&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224070019a6c78236&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2592959471","title":"双总裁时代的百济神州 还有哪些故事可讲？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592959471","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592959471?lang=zh_cn&edition=full","pubTime":"2025-12-19 23:31","pubTimestamp":1766158317,"startTime":"0","endTime":"0","summary":"12月19日，百济神州迎来新的人事调整。百济神州发布公告称，公司董事会同意聘任全球研发负责人汪来博士担任百济神州总裁，全球研发负责人。聘任生效后，汪来将担任百济神州总裁，全球研发负责人职务，负责管理百济神州研发、业务拓展以及业务联盟关系管理等职能。此外，百济神州方面还透露，吴晓滨仍然担任百济神州总裁、首席运营官COO，与汪来并列为双总裁。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512193597095415.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193597095415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK4526","BK1500","06160","ONC","688235","BK4585","BK1161","BK1583","BK1588","LU0307460666.USD","LU1719994722.HKD","LU1251922891.USD","LU0588546209.SGD","LU1770034418.SGD","LU1303224171.USD","BK0239","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2591376935","title":"TIGIT抗体再折戟：胃癌三期失败，免疫治疗前路何在？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591376935","media":"药事纵横","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591376935?lang=zh_cn&edition=full","pubTime":"2025-12-16 07:03","pubTimestamp":1765839790,"startTime":"0","endTime":"0","summary":"2025年12月12日，吉利德与Arcus Biosciences联合宣布，其PD-1+TIGIT+化疗一线治疗胃癌的三期临床STAR-221因无效而终止。这是TIGIT抗体赛道又一次重大挫折，也再次引发业界对免疫联合疗法靶点选择与临床策略的深刻反思。PD-1/TIGIT双抗可以同时阻断这两条免疫逃逸通路，恢复T细胞和NK细胞的活性，产生更强的抗肿瘤免疫反应 。PD-1/TIGIT双抗若能在临床试验中取得成功，将有望填补肿瘤免疫治疗领域的空白，满足未被满足的临床需求，市场潜力巨大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216070651a6a6b74b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216070651a6a6b74b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","LU2328871848.SGD","BK1583","BK1161","LU1303224171.USD","LU1719994722.HKD","06160","BK1588","LU0588546209.SGD","LU1969619763.USD","ONC","BK1500","LU1251922891.USD","LU1770034418.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":0.046},{"period":"3month","weight":-0.0637},{"period":"6month","weight":0.1412},{"period":"1year","weight":0.6089},{"period":"ytd","weight":0.1633}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"　　百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.083709},{"month":2,"riseRate":0.7,"avgChangeRate":0.03824},{"month":3,"riseRate":0.4,"avgChangeRate":-0.025903},{"month":4,"riseRate":0.4,"avgChangeRate":0.021288},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019094},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.147208},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,ONC,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}